Open AccessLong-term efficacy and safety of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes in Indian subgroup: Results from a 76-week extension trial of phase iii, double-blind, randomized study
Author(s) -
Sunil Gupta,
Shehla Shaikh,
Pooja Joshi,
Shraddha Bhure,
Viraj Suvarna
Publication year - 2017
Publication title -
indian journal of endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.456
H-Index - 28
eISSN - 2230-9500
pISSN - 2230-8210
DOI - 10.4103/ijem.ijem_517_16
Subject(s) - empagliflozin , medicine , type 2 diabetes , subgroup analysis , double blind , drug , term (time) , pharmacology , diabetes mellitus , alternative medicine , meta analysis , endocrinology , placebo , pathology , physics , quantum mechanics
Empagliflozin, a sodium glucose cotransporter-2 inhibitor, was recently evaluated in a randomized, controlled trial (RCT) in drug-naïve Type 2 diabetes mellitus (T2DM) patients managed on diet and exercise therapy. Efficacy and safety of empagliflozin in Indian subgroup of patients from a 76-week extension study of the initial multicentric RCT are reported in this article.